Stock Scorecard
Stock Summary for KalVista Pharmaceuticals Inc (KALV) - $11.07 as of 3/28/2024 2:32:30 PM EST
Total Score
8 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for KALV
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for KALV
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for KALV
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for KALV
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for KALV
Financial Details for KALV
Company Overview |
|
---|---|
Ticker | KALV |
Company Name | KalVista Pharmaceuticals Inc |
Country | USA |
Description | KalVista Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, discovers, develops, and markets small-molecule protease inhibitors for illnesses with unmet needs. The company is headquartered in Cambridge, Massachusetts. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 1/31/2024 |
Next Earnings Date | N/A |
Stock Price History |
|
Last Day Price | 11.07 |
Last Day Price Updated | 3/28/2024 2:32:30 PM EST |
Last Day Volume | 0 |
Average Daily Volume | 1,113,380 |
52-Week High | 16.88 |
52-Week Low | 7.21 |
Last Price to 52 Week Low | 53.54% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 100.07 |
Sector PE | 60.76 |
5-Year Average PE | -6.00 |
Free Cash Flow Ratio | 6.18 |
Industry Free Cash Flow Ratio | 12.70 |
Sector Free Cash Flow Ratio | 31.04 |
Current Ratio Most Recent Quarter | 5.44 |
Total Cash Per Share | 1.79 |
Book Value Per Share Most Recent Quarter | 2.56 |
Price to Book Ratio | 5.27 |
Industry Price to Book Ratio | 5.57 |
Sector Price to Book Ratio | 21.66 |
Price to Sales Ratio Twelve Trailing Months | 107.42 |
Industry Price to Sales Ratio Twelve Trailing Months | 13.94 |
Sector Price to Sales Ratio Twelve Trailing Months | 8.77 |
Share Statistics |
|
Total Shares Outstanding | 42,188,300 |
Market Capitalization | 467,024,481 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | -12.83% |
Reported EPS 12 Trailing Months | -3.12 |
Reported EPS Past Year | -2.38 |
Reported EPS Prior Year | -3.36 |
Net Income Twelve Trailing Months | -108,300,000 |
Net Income Past Year | -92,907,000 |
Net Income Prior Year | -82,339,000 |
Quarterly Revenue Growth YOY | 30.70% |
5-Year Revenue Growth | -42.71% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 75,586,000 |
Total Cash Past Year | 149,375,000 |
Total Cash Prior Year | 166,202,000 |
Net Cash Position Most Recent Quarter | 75,586,000 |
Net Cash Position Past Year | 149,375,000 |
Long Term Debt Past Year | 0 |
Long Term Debt Prior Year | 0 |
Total Debt Most Recent Quarter | 0 |
Equity to Debt Ratio Past Year | 1.00 |
Equity to Debt Ratio Most Recent Quarter | 1.00 |
Total Stockholder Equity Past Year | 161,025,000 |
Total Stockholder Equity Prior Year | 185,093,000 |
Total Stockholder Equity Most Recent Quarter | 88,583,000 |
Options |
|
Put/Call Ratio | 2.69 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.59 |
MACD Signal | -0.43 |
20-Day Bollinger Lower Band | 7.40 |
20-Day Bollinger Middle Band | 12.00 |
20-Day Bollinger Upper Band | 16.60 |
Beta | 0.90 |
RSI | 33.89 |
50-Day SMA | 10.53 |
200-Day SMA | 14.12 |
System |
|
Modified | 3/28/2024 11:17:51 PM EST |